During cancer progression and treatment, multiple subclonal populations of tumour cells
compete with one another, with selective pressures leading to the emergence of …

Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …

Lung cancer diagnosis is a challenge since it is also one of the most frequently diagnosed
cancers. Diagnostic challenges are deeply related to the development of personalized …

Introduction TP53 mutations are common in non-small cell lung cancer (NSCLC) and have
been reported as prognostic of poor outcome. The impact of TP53 co-mutations in epidermal …

Lung cancer is a leading cause of cancer-related mortality worldwide, and is classically
divided into two major histological subtypes: non-small-cell lung cancer (NSCLC) and small …

Chemotherapy is one of the basic treatments for cancers; however, drug resistance is mainly
responsible for the failure of clinical treatment. The mechanism of drug resistance is …

Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M …

Advances in the knowledge of the biology of non-small cell lung cancer (NSCLC) have
revealed molecular information used for systemic cancer therapy targeting metastatic …

Liquid biopsies appear to be a reliable alternative to conventional biopsies that can provide
both precise molecular data useful for improving the clinical management of lung cancer …

Introduction In the current era of personalized medicine, liquid biopsy has acquired a
relevant importance in patient management of advanced stage non-small cell lung cancer …